ClinicalTrials.gg
Status unknownNCT01277172TRENDUpdated Jan 14, 2011

TREatment of degeNerative and Neoplastic Diseases With Rituximab

A Phase 2/3 interventional study of Rituximab and Rituximab in Diffuse Large B Cell Lymphoma, sponsored by Probiomed S.A. de C.V.. Status unknown at 1 site in Mexico. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-01-14.

Sponsored by Probiomed S.A. de C.V. · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2011), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
85th of 211
54 · median 46
Started
2010
with 8 others
Phase 2/3
2 of 218
none open now
Registered
112th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 85th largest by planned enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2010, is one of 2 in phase 2/3, and was the 112th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in combination with CHOP in previously untreated patients with diffuse B cells Non Hodgkin lymphoma.

Read the detailed description

At present R-CHOP (Rituximab plus Cyclofosfamide, Doxorrubicine, Vincristine and Prednisone) has became standard of care of patients with B cells Non Hodgkin Lymphoma CD20+.

Study will perform pharmacodynamic (PD) and pharmacokinetic (PK) measurment of a novel Rituximab in comparison with Mabthera and evaluates safety both metabolic as well immunologic.

Study protocolo is designed to provide data on impact of treatment interchange of both study drugs (PBO-326 and Mabthera).

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • DLBCL
  • pharmacokinetics
  • pharmacodynamics
  • Rituximab
  • LymphomaLymphoma
  • Non-HodgkinLymphoma
  • B-CellLymphoma
  • Large B-Cell
  • Disorders Lymphatic Diseases
  • Immunoproliferative Disorders
  • Antineoplastic Agents
  • Adverse Effects
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed subjects with a confirmed pathologic diagnosis of diffuse large B cell non-Hodgkin's lymphoma (DLBCL) based on the 2008 World Health Organization classification.
  2. CD20+ lymphoma cells at screening.
  3. > 18 years of age at screening.
  4. Ann Arbor Stages I-IV at screening.
  5. Any IPI score at screening.
  6. Easten Cooperative Oncology Group () performance status (0-2) or scale > 60 at screening.
  7. > 50%.
  8. Willing and able to provide written prior to performing study procedures.
  9. Women of must use effective methods starting from screening and until 12 months following the last infusion.

Exclusion criteria

Exclusion Criteria:

  1. Hodgkin lymphoma.
  2. Any lymphoma other than CD20+ Diffuse Large B Cell Lymphoma (DLBCL).
  3. Immunodeficiency syndrome or (HIV) seropositivity .
  4. Active uncontrolled infection (viral, bacterial or fungal infection) requiring systemic therapy at screening and/or at baseline visit.
  5. Function Liver tests >2 x upper normal values.
  6. Positive surface antigen or antibodies to .
  7. Any other serious active disease or co-morbid medical condition.
  8. Subjects who, according to the investigator, are likely to be non-compliant or uncooperative during the study.
  9. Pregnant or breast-feeding women or women that intend to get pregnant during study or within 12 months following the last infusion.
  10. Treatment with any drug within 90 days before day 1 of study treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Group 1 / PBO-326

    This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.

    Biological: Rituximab

  • Active comparator
    Group 2 / Mabthera

    This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.

    Biological: Rituximab

  • Experimental
    Group 3 / PBO-326

    This group will be treated six cycles with PBO-326

    Biological: Rituximab

  • Active comparator
    Group 4 / Mabthera

    This group will be treated six cycles with Mabthera

    Biological: Rituximab

Interventions

  • BiologicalRituximab

    375 mg/m2 IV every 2 weeks for 6 cycles

    Also known as: Monoclonal Antibody against CD20

  • BiologicalRituximab

    375 mg/m2 IV every 2 weeks for 6 cycles

    Also known as: Monoclonal Antibody against CD20

  • BiologicalRituximab

    375 mg/m2 IV every 2 weeks for 6 cycles

    Also known as: Monoclonal Antibody against CD20

  • BiologicalRituximab

    375 mg/m2 IV every 14 days for 6 cycles

    Also known as: Monoclonal antibody against CD20

06

What researchers measure

Primary outcomes

  1. Basal and final serum CD 20 levels comparison.

    Primary outcome is the depletion of CD20+ B cells. This will be measured every 14 days and comparison will be made basal levels versus visit 2, visit 3, visit 4, visit 5, visit 6, visit 7 and visit 8.

    Time frame: Every 14 days for the duration of treatment

Secondary outcomes

  1. Comparison of safety of PBO-326 versus Mabthera

    Adverse events will be observed and recorded in relation to acute infusion events (number of cases and severity of hypotension, hipertension, headache, and all cardiovascular events previously reported by Mabthera) as well as long term effects over key hematological cells (number of cases and severity of neutropenia, trombocytopenia, leucopenia) per visit.

    Time frame: Every 14 days measurements

07

Study locations

1 of 1 sites recruiting
  • INCan
    Mexico, D.f. 14080, Mexico
    Recruiting
    • Ramiro Espinoza Zamora, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Sep 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2011
First posted
Jan 14, 2011
Start
Oct 2010
Primary completionEst.
Sep 2011
CompletionEst.
Oct 2011
Last update
Jan 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01277172
Lead sponsor
Probiomed S.A. de C.V.
First posted
Jan 14, 2011
Start date
Oct 2010
Primary completion
Sep 2011 (estimated)
Completion
Oct 2011 (estimated)
Last update
Jan 14, 2011

Study contacts

Jorge Revilla Beltri, MD
Contact
jorge.revilla@probiomed.com.mx
(00+1) 55 25811969
Aaron Molina Perez, MD
Contact
ignacio.molina@probiomed.com.mx
(00+1) 55 25811924
Jorge Revilla Beltri, MD
study director · Probiomed S.A. de C.V.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion